KRAS and acute myeloid leukemia: Interestingly, 37% of patients with AML who failed Gilteritinib therapy exhibited RAS/MAPK mutations as well as the emergence of additional new mutations (including BRAF, CBL, KRAS, PTPN11, RUNX1, WT1, and CEBPA), which were undetected prior to Gilteritinib treatment (2).